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Background: At the intervention for cardiovascular disease (CVD), albuminuria is a new 
pivotal target. Calcium channel blocker (CCB) is one of the most expected agents. Currently 
CCBs have been classified by delivery system, half-life and channel types. We tested 
anti-albuminuric effect among 4 types of CCBs.  
Methods: Subjects were 50 hypertensives (SBP/DBP 164.7±17.1/92.3±12.2 mmHg, s-Cr 
0.81±0.37 mg/dl, urinary albumin excretion (UAE) 69.4 (33.5-142.6) mg/gCr). Four CCBs 
were administered in a crossover setting; nifedipine CR, a long biological half-life L type by 
controlled release, cilnidipine, an N/L type, efonidipine, a T/L type and amlodipine, a long 
biological half-life L type.  
Results: Comparable BP reductions were obtained. UAE at endpoints ware as follow (mg/gCr, 
*P<0.01): nifedipine CR 30.8 (17.3-81.1),* cilnidipine 33.9 (18.0-67.7),* efonidipine 51.0 
(21.2-129.8), amlodipine 40.6 (18.7-94.7). By all agents, significant augmentations were 
observed in PRA, angiotensin I and angiotensin II (AngII). AngII at cilnidipine was 
significantly lower than that at amlodipine. PAC at cilnidipine and efonidipine was 
significantly lower than that at amlodipine. Nifedipine CR significantly reduced ANP 
concentration.  
Conclusions: It is revealed that only nifedipine CR and cilnidipine could reduce albuminuria 
statistically. Thus, it is suggested that the 2 CCBs might be favorable for organ protection in 
hypertensives.  
 
1. Introduction  
Recent studies have revealed that proteinuria and albuminuria are risk factors for end stage 
renal disease and at the same time risk factors for cardiovascular disease (CVD) [1-3]. 
Reduction in proteinuria and/or albuminuria is associated with a trend in reducing renal death 
and cardiovascular events [4,5]. These results extend the new concept that high 
albuminuria/proteinuria itself should be the target for reducing hard end points just like 
established treatments for high blood pressure, high blood glucose and high LDL cholesterol. 
Thus, in other words, at the intervention of hypertension, albuminuria reduction is one of the 
most pivotal surrogate goals for hypertension treatment as well as strict blood pressure (BP) 
control for the final goals, reducing renal death and CVD. Blockade of the renin-angiotensin 
system (RAS) is essential for albuminuria. Agents such as angiotensin converting enzyme 
(ACEI) and angiotensin II receptor blocker (ARB) reduce albuminuria and consequent renal 
and cardiovascular events in diabetic subjects [6,7]. However, in many cases, additional 
anti-hypertensive drugs are indispensable to obtain the target BP levels. One of the most 
expected candidates is calcium channel blocker (CCB), which is a useful agent with a sure BP 
reduction and no crucial adverse effect. Several studies revealed that combination of RAS 
blockade agents with some CCBs reduce albuminuria additionally [8]. However glomerular 
hypertension and the RAS activation provoked by CCBs are unfavorable characteristics. 
because the RAS plays major roles in blood pressure regulation and electrolyte metabolism 
[9], at the same time, the over-activation of the RAS is thought to play pivotal roles in the 
pathophysiology of cardiovascular [10], renal [11] and metabolic conditions [12]. The 
activation of the system by CCB is thought to be inevitable via intra-cellular calcium 
reduction and sympathetic nerve activation from the transcriptional level of the human renin 
gene [13-17]. Recently Ca channels are classified into at least five subtypes based on 
electrophysiological and pharmacological characteristics, namely, L-, N-, P/Q-, R- and T-types 
[18,19]. Currently, several types of CCBs are available and have been classified from the 
respects of biological half-life, drug delivery system and blocking channel types and a new 
classification of dihydropyridines according to the sympathetic nerve effects has been 
proposed [20]. The purpose of the study is to compare anti-albuminuric effect as the primary 
endpoint and the level of the circulatory RAS activation among 4 types of CCBs by a 
simplified crossover manner.  
 
2. Materials and methods  
 
2.1. Subjects and Treatment  
 
 We enrolled 58 consecutive hypertensives of our out clinic into the study and 50 subjects 
completed the study (Figure 1). All subjects were Japanese. Subjects with age less than 20 
years old, secondary hypertension, acute phase disorder and severe organ failure were 
excluded. All subjects had been under the condition without any anti-hypertensive or 
anti-dyslipidemic agents at least 1 week before the first sampling for the study and thereafter 
anti-dyslipidemic agents were restarted. All other medications needed other than 
anti-hypertensive drugs were freely prescribed according to each patient disorder. Especially, 
diabetic subjects, 30.0% of the total subjects, which is thought to be standard prevalence in 
Japan, continued to receive their usual care for diabetes. A target glycosylated hemoglobin 
A1c level of less than 6.5% was recommended for all subjects. All subjects were guided to 
take dietary NaCl less than 6 gram daily. Home blood pressure was measured for excluding 
the subjects with white coat hypertension. At out clinic, on each occasion, blood pressure was 
taken at least three readings separated by as much time as practical with an automated digital 
device (Terumo, ES-H51). If readings varied more than 5 mmHg, additional readings were 
taken until the last two were close. Diabetes was diagnosed according to the criteria of the 
World Health Organization. Dyslipidemia was diagnosed according to the criteria of the 
International Diabetes Federation. The body mass index (BMI) was calculated as the weight 
in kilograms divided by the square of the height in meters. Arterial hypertension was defined 
as a systolic blood pressure (SBP) of 140 mmHg or more or a diastolic blood pressure (DBP) 
of 90 mmHg or more in the sitting position on two separate occasions in the morning. Daily 
20-60 mg of nifedipine CR or 10-20 mg of cilnidipine or 20-60 mg of efonidipine or 5-10 mg 
of amlodipine besilate was administered to subjects and titrated to achieve a target blood 
pressure, 130/80 mmHg (140/90 mmHg in the elderly), for 12 weeks in a randomized 4 
groups 4 terms cross-over manner (Figure 1). Actually the subjects were seen twice or thrice 
in each period and compliance for the medication was checked by interview. The authors of 
this manuscript have certified that they comply with the Principles of Ethical Publishing in the 
International Journal of Cardiology: Shewan LG and Coats AJ. Ethics in the authorship and 
publishing of scientific articles. Int J Cardiol 2010;144:1-2.  
 
2.2. Study Measures  
 
At the baseline day and the last day of the 12 weeks administration of each drug, the items 
shown in Table1, Table 2 and Table 3 were examined. The samples were obtained once at 
each drug tested period in the forenoon. Urinary albumin excretion (UAE) was measured by 
immunoturbidimetry. At the run-in period, we measured urinary albumin several times and 
confirmed albuminuria at least 2 times of 3 measurements including the baseline points 
according to K-DOQI Guidelines 2007 [21]. Estimated glomerular filtration rate (eGFR) was 
calculated according to the formula for Japanese subjects: eGFR (ml/min/1.73m2) =194 x 
Cr-1.094 x Age-0.287 (x 0.739, in the case of female). After 15 minutes rest in the supine position, 
blood samples were drawn for the measurement. For avoiding cold activation and degradation 
of humoral factors, the plasma samples were frozen as soon as possible. For plasma renin 
activity (PRA) measurement sample were incubated 37 °C for adequate hours and generated 
angiotensin I was measured by radioimmunoassay with a commercial kit (BML, Japan). 
Angiotensin I (AngI) and angiotensin II (AngII) were assayed by radioimmunoassay with 
commercial kits (SRL, Japan). Plasma aldosterone concentration (PAC) and atrial natriuretic 
peptide (ANP) were assayed by radioimmunoassay with commercial kits (BML, Japan).  
 
2.3. Statistical Analyses  
 
 As the distribution of UAE, the primary endpoint of the study, is deviated, the needed 
sample size estimation is difficult. So that it was tentatively calculated estimating a standard 
deviation for UAE of about 100 mg/gCr; a difference to be detected between groups of 40 
mg/gCr and used a bilateral paired Student’s t-test with protection against type I error of 5% 
and 80% of power. Thus, it was calculated the study required around 50 subjects in total 
tentatively. Actually differences of UAE were analyzed by Wilcoxon signed rank test. 
Statistical analyses were performed with SPSS Version 17.0 (SPSS Japan, Inc., Japan). Data 
were presented as numbers, percentage, means±SD or medians (interquartile ranges), as 
appropriate. The differences between 2 paired continuous variables were analyzed by 
Student’s t-test fundamentally or Wilcoxon signed rank test when data do not show normal 
distribution. All P values are two-sided.  
 
3. Results  
 
3.1. Study course and blood pressure 
 
 From 58 enrolled cases, a total of 50 subjects completed the cross-over study; 
monotherapy of nifedipine CR, cilnidipine, efonidipine or amlodipine besilate by turns for 12 
weeks each. Three patients dropped out because of palpitation, eruption or edema in each one 
case for nifedipine CR. One patient dropped out because of palpitation for cilnidipine. Two 
patients dropped out because of insufficient blood pressure reduction for efonidipine. Two 
patients dropped out because of gingivitis or edema in each one case for amlodipine. However, 
including the 8 cases, no serious adverse effect occurred in the study term. The major 
demographic and baseline clinical characteristics were summarized in Table 1, Table 2 and 
Table 3. Final doses of nifedipine CR, cilnidipine, efonidipine and amlodipine were 33.6±9.4 
mg/day, 14.1±5.1 mg/day, 44.8±13.7mg/day and 6.6±2.7 mg/day, respectively. Changes in 
blood pressure and pulse rate are summarized in Table 2. With each CCB administration, 
significant reductions in systolic and diastolic blood pressure from baseline were achieved. 
The BP reductions are comparable between each combination comparison. No significant 
change was observed in pulse rates from baseline and no significant difference was observed 
among the drugs.  
 
3.2. Urinary albumin excretion and humoral factors 
 
 As shown in Figure 2, UAE at endpoints of each CCB were as follow: nifedipine CR 30.8 
(17.3-81.1), cilnidipine 33.9 (18.0-67.7), efonidipine 51.0 (21.2-129.8), amlodipine 40.6 
(18.7-94.7). Thus, in spite of the comparable BP reduction levels, it is revealed that only 
nifedipine CR and cilnidipine could reduce UAE significantly among 4 tested CCBs. The 
exact P values from baseline were, 0.002, 0.003, 0.325 and 0.077 for nifedipine CR, 
cilnidipine, efonidipine and amlodipine, respectively.  
 With regard to humoral factors (Table 3), by all agents, significant augmentations were 
observed in PRA, AngI and AngII concentrations. AngII concentration at cilnidipine was 
significantly lower than that at amlodipine. PAC at cilnidipine and efonidipine was 
significantly lower than that at amlodipine. Nifedipine CR significantly reduced ANP 
concentration.  
 
4. Discussion  
 Recent studies have revealed that at the intervention of hypertension, albuminuria 
reduction is one of the most pivotal surrogate goals for reducing renal death and CVD as well 
as strict BP control [4,5]. CCB is one of the most expected agents for albuminuria next to the 
RAS blocking agents. Especially, N- and T-type Ca channel blocking agents are thought to 
have dilating effects on efferent glomerular arterioles as well as afferent ones, resulting in 
lesser glomerular hypertension [22,23]. However, it has not been clarified which CCB could 
reduce albuminuria/proteinuria until now. Thereby we tested anti-albuminuric effects of 4 
representative types of CCBs; nifedipine CR, a long biological half-life L type CCB with 
controlled release system, cilnidipine, an N/L type CCB, efonidipine, a T/L type CCB and 
amlodipine besilate, a long biological half-life L type CCB with trans-membrane approach. 
Our results revealed that nifedipine CR and cilnidipine could reduce albuminuria. Previous 
studies demonstrated the reducing effects of albuminuria/proteinuria by nifedipine [24] and 
cilnidipine [25-27] in the combination of RAS blockade therapy. As a design of monotherapy, 
albuminuria reduction was observed by cilnidipine compared with amlodipine [28]. Finally, 
for the first time, our study could indicate that significant albuminuria reduction was obtained 
by nifedipine CR and cilnidipine in a comparison among 4 types of CCBs as a monotherapy. 
The difference of effect for morning blood pressure among CCBs might be considered for the 
results, as the diurnal blood pressure such as morning surge is supposed to be related with 
UAE [29].  
 CCB administration is thought to give rise to considerable changes in humoral factors. 
Especially, at the human renin gene, cAMP response element (CRE) and negative calcium 
responsive element (nCaRE) has been characterized [13-17] i.e., sympathetic nerve activation 
and intra-cellular calcium reduction provoked by CCBs up-regulate the transcription of the 
renin gene via catecholamines-β1 adrenoceptor-cAMP-CREB-CRE pathway and intra-cellular 
Ca-Ref1-nCaRE pathway. Consequently CCB is thought to give rise to over-activation of 
whole cascades of the RAS. Our results of the study indicate that, by all CCBs tested, 
significant augmentations were observed in PRA, AngI and AngII concentrations as expected. 
However, PRA and AngI at cilnidipine tended to be low compared to those at the other CCBs 
and Ang II and PAC were significantly lower than those at amlodipine. This phenomenon of 
less activation of the RAS by cilnidipine compared to amlodipine was already shown in 
animals and human subjects [30-32] explained by N-type calcium channel’s regulation of 
norepinephrine release [33] and N-type calcium channel suppression and reduction of 
norepinephrine secretion rate by cilnidipine [34,35]. On the other hand, PAC at cilnidipine and 
efonidipine was significantly lower than that at amlodipine. For cilnidipine the result could be 
explained by the less activation of RAS. A recent report suggests that cilnidipine suppressed 
the development of proteinuria greater than amlodipine possibly through inhibiting N-type 
calcium channel-dependent podocyte injury in SHR/ND [36]. For efonidipine, the result might 
be explained by suppression effect on transcription of aldosterone synthase (CYP11B2) [37]. 
Finally nifedipine CR significantly reduced ANP concentration. This might be explained by 
recently suggested mineralocorticoid receptor antagonist activity of a number of 
dihydropyridine CCB with nifedipine being stronger than amlodipine [38]. Anyway, 
anti-albuminuric effects could be explained not only by the difference of blocking channel 
types of each agent but some original pleiotropic effect, for example, effects on transcriptional 
mechanisms [39,40].  
 Several limitations of this study should be noted. Considering the earnest practical limit 
for clinical human subjects, washout period between the 2 drugs administration was not set up. 
The sample number may be still relatively small. Although primary endpoint of the study was 
changes in albuminuria from baseline clearly, we used multiple statistical comparisons for 
between 2 drugs and humoral factors additionally as sub-analysis with significance level 0.05. 
Although population admixture is thought to contribute to concordant results among studies, 
our study is comprised of only Japanese population. On the contrary, inhomogeneous 
subjects’ selection including 30% diabetics could be a source of bias in pathogenic 
mechanism. Again recently RAS blockade agent is gold standard therapy for prevent 
microalbuminuria in diabetes [41]. Considering the suggested target by guidelines and the 
renal autoregulation [42] , the obtained blood pressure reduction might not be sufficient due to 
the mild target blood pressure in the elderly. Our study design could not provide natural 
history of albuminuria independent of blood pressure reduction. And one another limitation 
was that the achieved systolic blood pressure differed by about 2 mmHg although it did not 
reach statistic difference.  
 It is suggested that, in respect of albuminuria reduction, nifedipine CR and cilnidipine 
may have favorable characteristics for organ protection. These differences seem to be 
explained by some original pleiotropic effect as well as the blocking channel types of each 
agent. In addition to albuminuria, other organ damage markers such as left ventricular 
hypertrophy and retinal changes might be useful for evaluation for anti-hypertensive agents. 
Further investigations should be necessary for appropriate adoption of drug including 
elucidation of predictors for responder as indicated at ARB [43].  
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Figure 1. Schematic Protocol of a Randomized Crossover Study. Four types of calcium 
channel blockers were administered to subjects for 12 weeks each in a randomized 4 groups 4 
terms cross-over manner. A: Amlodipine, B: Cilnidipine, C: Efonidipine, D: NifedipineCR.  
 
 
Table 1. Baseline Characteristics of Subjects*  
Characteristics  
Number 50 
Age — yr 69.8±10.8 
Male sex — no. (%) 22(44.0%) 
Body-mass index† 24.2±3.6 
Waist circumference — cm 86.7±10.1 
Metabolic syndrome, no. (%) 16 (32.0%) 
Diabetes mellitus, no. (%) 15 (30.0%) 
Dyslipidemia no. (%) 31 (62.0%) 
Glucose — mg/dl 109.3±23.7 
Glycosylated hemoglobin — % 5.57±0.79 
Triglyceride — mg/dl‡ 110 (77.0-145.0) 
Cholesterol — mg/dl  
High-density lipoprotein‡ 53.5(47.0-61.0) 
Low-density lipoprotein 110.6±27.4 
Serum creatinine — mg/dl 0.81±0.37 
Estimated GFR— ml/min/1.73m2 68.7±20.2 
Angiotensin converting enzyme — IU/l 14.7±4.3 
Urinary natrium excretion — mEq/creatinine‡ 203.5 (105.1-282.0)  
Urinary kalium excretion — mEq/ creatinine‡ 49.3 (34.6-80.2)  
Urinary chlorine excretion — mEq/ creatinine‡ 198.8 (108.2-313.1)  
*Plus-minus values are means ± SD.  
†The body-mass index is the weight in kilograms divided by square of the height in meters.  
‡Values shown are medians (interquartile ranges).  
 
Table 2. Blood Pressure and Heart Rate of Each Drug Administration* 
Characteristics  Baseline  Nifedipine CR  Cilnidipine  Efonidipine  Amlodipine  
Blood pressure (mmHg)      
Systolic  164.7±17.1 139.1±15.2† 137.2±13.0† 139.5±17.0† 137.6±11.6†  
Diastolic  92.3±12.2 79.6±9.2† 79.2±10.1† 77.5±12.6† 79.0±10.6†  
Pulse rate (beats/ min)   74.0±11.4   73.8±13.4 73.9±11.3 72.9±10.6 74.5±13.2 
*Plus-minus values are means ± SD. 
†P<0.05 for the comparison with Baseline. The differences between 2 paired continuous variables were 




Figure 2. Urinary Albumin Excretion at the Endpoint of Each Calcium Channel Blocker 
Administration. Boxes express the interquartile ranges and horizontal lines in the boxes 
express the medians. * P<0.01 for the comparison with Baseline. †P<0.05 for the comparison 
with Efonidipine. The exact P values from baseline were, 0.002, 0.003, 0.325 and 0.077 for 
nifedipine CR, cilnidipine, efonidipine and amlodipine, respectively. The differences were 
analyzed by Wilcoxon signed rank test. All P values are two-sided.  
 
Table 3. Effects of Each Calcium Channel Blocker on Humoral Factors* 
Characteristics Baseline Nifedipine CR Cilnidipine Efonidipine Amlodipine 
PRA (ng/mL/hr) 0.60±0.71 1.19±1.34† 0.97±0.86† 1.20±1.63† 1.27±1.53† 
Angiotensin I (pg/mL) 56.8±40.0 107.3±89.4† 93.5±72.7† 131.5±165.6† 98.0±73.2† 
Angiotensin Ⅱ(pg/mL) 4.7±4.2 8.3±5.9† 8.6±5.5†‡ 13.7±18.6† 9.0±5.9†‡ 
PAC (pg/mL) 76.7±41.8 86.5±43.9§ 75.0±39.5§‡ 74.5±30.2|| 86.7±45.0‡|| 
ANP (pg/mL) 39.3±24.6 29.7±18.2†¶ ∫ 32.3±19.3** 43.1±20.6∫**|| 36.5±27.3¶ || 
*Plus-minus values are means ± SD. The differences between 2 paired continuous variables were analyzed 
by Student’s t-test. All P values are two-sided.  
† P<0.05 for the comparison with Baseline  
‡P<0.05 for the comparison with Cilnidipine vs Amlodipine  
§P<0.05 for the comparison with Nifedipine CR vs Cilnidipine  
|| P<0.05 for the comparison with Efonidipine vs Amlodipine  
¶ P<0.05 for the comparison with Nifedipine CR vs Amlodipine  
∫ P<0.05 for the comparison with Nifedipine CR vs Efonidipine  
** P<0.05 for the comparison with Cilnidipine vs Efonidipine  
 
